RDB15492 - pENTER-EGFR C797S/T790M/del19

Resource data sheet
Prev.
Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

pENTER-EGFR C797S/T790M/del19

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.

Catalog number	RDB15492
Resource name	pENTER-EGFR C797S/T790M/del19
Clone info.	Gateway(R) entry vector of human epidermal growth factor receptor (EGFR) mutant, C797S, T790M, and deletion in exon 19, EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.
Comment	cDNA was obtained from HCC-827 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction).
Vector backbone	pENTR (plasmid)
Size of vector backbone	2.6 kb
Selectable markers	Kan^r
Gene/insert name	human EGFR cDNA
Depositor\|Developer	Katayama, Ryohei \|

Other clones in our bank

human EGFR

External Database
human EGFR

Reference sequence

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Terms and conditions set forth by the DEPOSITOR In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)

Ordering Please visit Information of Request for Distribution.[link]
Order form [Credit Card Payment] [Bank Transfer Payment]
Material Transfer Agreement (MTA for use for not-for-profit academic purpose) [Word]

Remarks
Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.

提供案内 (日本国内) [open/close]

Terms and conditions set forth by the DEPOSITOR	In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
Ordering	Please visit Information of Request for Distribution.[link] Order form [Credit Card Payment] [Bank Transfer Payment] Material Transfer Agreement (MTA for use for not-for-profit academic purpose) [Word]
Remarks	Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.

提供条件	利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Uchibori, K et al. Nat. Commun. 8: 14768, 2017)。
提供依頼	手続きの詳細は、「提供申込みについて[link]」をご覧ください。提供依頼書 [Word] 提供同意書 (MTA、非営利機関による非営利学術研究用)[Word]
備考	Gateway®テクノロジーを用いたエントリークローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB15492	pENTER-EGFR C797S/T790M/del19	DNA solution

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

References and tips

Electronic file

Original reference

original	Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083.

Further references such as user reports and related articles (go to bottom)

Sequence information

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet	RDB15492_A7K8p1-1.pdf

Nucleotide sequence of a portion of this resource (if available).

Primer: rrnBT1ter_F2 Region: rrnB T1 ter, attL1, insert 5' Sequence file: RDB15492_A7K8a.seq
>D04925A5_A7K8_2_rrnBT1ter_F2_E04_13_ABI24.ab1 1 AGCAGATCTT CGACTGAGCC TTTCGTTTTA TTTGATGCCT GGCAGTTCCC TACTCTCGCG 61 TTAACGCTAG CATGGATGTT TTCCCAGTCA CGACGTTGTA AAACGACGGC CAGTCTTAAG 121 CTCGGGCCCC AAATAATGAT TTTATTTTGA CTGATAGTGA CCTGTTCGTT GCAACAAATT 181 GATGAGCAAT GCTTTTTTAT AATGCCAACT TTGTACAAAA AAGCAGGCTC CGCGGCCGCC 241 CCCTTCACCA TGCGACCCTC CGGGACGGCC GGGGCAGCGC TCCTGGCGCT GCTGGCTGCG 301 CTCTGCCCGG CGAGTCGGGC TCTGGAGGAA AAGAAAGTTT GCCAAGGCAC GAGTAACAAG 361 CTCACGCAGT TGGGCACTTT TGAAGATCAT TTTCTCAGCC TCCAGAGGAT GTTCAATAAC 421 TGTGAGGTGG TCCTTGGGAA TTTGGAAATT ACCTATGTGC AGAGGAATTA TGATCTTTCC 481 TTCTTAAAGA CCATCCAGGA GGTGGCTGGT TATGTCCTCA TTGCCCTCAA CACAGTGGAG 541 CGAATTCCTT TGGAAAACCT GCAGATCATC AGAGGAAATA TGTACTACGA AAATTCCTAT 601 GCCTTAGCAG TCTTATCTAA CTATGATGCA AATAAAACCG GACTGAAGGA GCTGCCCATG 661 AGAAATTTAC AGGAAATCCT GCATGGCGCC GTGCGGTTCA GCAACAACCC TGCCCTGTGC 721 AATGTGGAGA GCATCCAGTG GCGGGACATA GTCAGCAGTG ACTTTCTCAG CAACATGTCG 781 ATGGACTTCC AGAACCACCT GGGCAGCTGC CAAAAGTGTG ATCCAAGCTG TCCCAATGGG 841 AGCTGCTGGG GTGCAGGAGA GGAGAACTGC CAGAAACTGA CCAAAATCAT CTGTGCCCAG 901 CAGTGCTCCG GGCGCTGCCG TGGCAAGTCC CCCCAGTGAC TGCTGCCACA ACCAGTGTGC 961 TGCAGCTGCA CAGGGCCCCC GGGAGAGCGA CTGCCCTGGT CTGCCGCAAA TTCCCGAGAC 1021 GAAGCCACGT GCAAAGGACA CCTGCCCCCC CCACTTCATG CTTCTTACAA CCCCCACCAC 1081 GTTAACCAGA TGATGTGAAC CCCGAGGTCA AAATAACAGG CCTTTTGGGA AGC //
Primer: pDONR_R Region: attL2, insert 3' Sequence file: RDB15492_A7K8b.seq
>D04925A5_A7K8_2_pDONR_R_E08_14_ABI24.ab1 1 GGCGGACGGC AGGACGCTAT GACCATGTAA TACGACTCAC TATAGGGGAT ATCAGCTGGA 61 TGGCAAATAA TGATTTTATT TTGACTGATA GTGACCTGTT CGTTGCAACA AATTGATAAG 121 CAATGCTTTC TTATAATGCC AACTTTGTAC AAGAAAGCTG GGTCGGCGCG CCCACCCTTT 181 CATGCTCCAA TAAATTCACT GCTTTGTGGC GCGACCCTTA GGTATTCTGC ATTTTCAGCT 241 GTGGAGCCCT TAAAGATGCC ATTTGGCTTG GCTTCCTTGG GAAAGAAGTC CTGCTGGTAG 301 TCAGGGTTGT CCAGGCTAAT TTGGTGGCTG CCTTTCTGGG CCCAGTGGGC AGGGCTGTCG 361 AATGTGCTGT TGACACAGGT GGGCTGGACA GTGTTGAGAT ACTCGGGGTT GCCCACTGCA 421 GTGCTGTGGG GGTCCTGGTA GTGTGGGTCT CTGCTGGGCG CGGGGTTCAG AGGCTGATTG 481 TGATAGACAG GATTCTGCAC AGAGCCAGCG GGCCTTTTGG GAACGGACTG GTTTATGTAT 541 TCAGGCACTG GGAGGAAGGT GTCGTCTATG CTGTCCTCAG TCAAGGCGCC TGTGGGGTCT 601 GAGCTGTATC GCTGCAAGAA GCTGTCTTCC TTGATGGGAC AGCTTTGCAG CCCATTTCTA 661 TCAATGCAAG CCACGGTGGA ATTGTTGCTG GTTGCACTCA GAGAGCTCAG GAGGGGAGTC 721 CGTGACGTGG AGGGGCTGCT GAAGAAGCCC TGCTGTGGGA TGAGGTACTC GTCGGCATCC 781 ACCACGTCGT CCATGTCTTC TTCATCCATC AGGGCACGGT AGAAGTTGGA GTCTGTAGGA 841 CTTGGCAAAT GCATTCTTTC ATCCCCCTGA ATGACAAGGT AGCGCTGGGG GGTCTCGGGC 901 CATTTTGGAG AATTCGATGA TCAACTCACG GAACTTTGGG CGACTATCTG CGTCTATCAT 961 CCAGCACTTG ACCATGATCA TGTAGACATC GATGGTACAT ATGGGTGGCT GAGGAGGGCG 1021 TTTCTCCTTT CTCCAGGATG GAGGAGATTC TCGGCTGGGC AGGATTCCCG TCATATGACT 1081 GGAATTCTAA AGGTCAATCC AACTTCCCAA AACCG //
Primer: EGFR-F5 Region: insert middle region (C797S, T790M, del19) Sequence file: RDB15492_A7K8c.seq
>D04925A5_A7K8_2_EGFR-F5_E09_15_ABI24.ab1 1 AACATTAATC CGTCATCGCC ACTGGGATGG TGGGGGCCCT CCTCTTGCTG CTGGTGGTGG 61 CCCTGGGGAT CGGCCTCTTC ATGCGAAGGC GCCACATCGT TCGGAAGCGC ACGCTGCGGA 121 GGCTGCTGCA GGAGAGGGAG CTTGTGGAGC CTCTTACACC CAGTGGAGAA GCTCCCAACC 181 AAGCTCTCTT GAGGATCTTG AAGGAAACTG AATTCAAAAA GATCAAAGTG CTGGGCTCCG 241 GTGCGTTCGG CACGGTGTAT AAGGGACTCT GGATCCCAGA AGGTGAGAAA GTTAAAATTC 301 CCGTCGCTAT CAAGACATCT CCGAAAGCCA ACAAGGAAAT CCTCGATGAA GCCTACGTGA 361 TGGCCAGCGT GGACAACCCC CACGTGTGCC GCCTGCTGGG CATCTGCCTC ACCTCCACCG 421 TGCAGCTCAT CATGCAGCTC ATGCCCTTCG GCTCCCTCCT GGACTATGTC CGGGAACACA 481 AAGACAATAT TGGCTCCCAG TACCTGCTCA ACTGGTGTGT GCAGATCGCA AAGGGCATGA 541 ACTACTTGGA GGACCGTCGC TTGGTGCACC GCGACCTGGC AGCCAGGAAC GTACTGGTGA 601 AAACACCGCA GCATGTCAAG ATCACAGATT TTGGGCTGGC CAAACTGCTG GGTGCGGAAG 661 AGAAAGAATA CCATGCAGAA GGAGGCAAAG TGCCTATCAA GTGGATGGCA TTGGAATCAA 721 TTTTACACAG AATCTATACC CACCAGAGTG ATGTCTGGAG CTACGGGGTG ACCGTTTGGG 781 AGTTGATGAC CTTTGGATCC AAGCCATATG ACGGAATCCC TGCCAGCGAG ATCTCCTCCA 841 TCCTGGAGAA AGGAGAACGC CTCCCTCAGC CACCCATATG TACCATCGAT GTCTACATGA 901 TCATGGTCAA GTGCTGGATG ATAGACGCAG ATAGTCGCCC AAAGTTTCCG TGAGTTGATC 961 ATCGAATTCT CCCAAAATGG CCCGAGACCC CCAGCGCTAC CCTTTGTCAT TCAGGGGGAT 1021 GAAAGATGCA TTTGCCAGTC CCTACAGGAC TCTACTTCTA CGTGCCCTGA TGTATGAAGA 1081 AGACATCACG GAACGTCTTG GAATGCT //

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original	Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083.

2022.05.17

GNP_filter3_RDBDEP_html_220516.pl